A detailed history of Goldman Sachs Group Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 124,672 shares of CSTL stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,672
Previous 80,389 55.09%
Holding current value
$2.71 Million
Previous $1.73 Million 59.23%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.06 - $25.3 $799,750 - $1.12 Million
44,283 Added 55.09%
124,672 $2.76 Million
Q4 2023

Feb 13, 2024

SELL
$12.19 - $22.43 $869,902 - $1.6 Million
-71,362 Reduced 47.03%
80,389 $1.73 Million
Q3 2023

May 14, 2024

BUY
$13.28 - $20.3 $947,687 - $1.45 Million
71,362 Added 88.77%
151,751 $2.56 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $929,998 - $1.42 Million
70,030 Added 85.69%
151,751 $2.56 Million
Q2 2023

May 14, 2024

SELL
$11.66 - $26.0 $655,210 - $1.46 Million
-56,193 Reduced 40.74%
81,721 $1.12 Million
Q2 2023

Aug 14, 2023

SELL
$11.66 - $26.0 $655,210 - $1.46 Million
-56,193 Reduced 40.74%
81,721 $1.12 Million
Q1 2023

May 14, 2024

SELL
$19.47 - $28.49 $2.12 Million - $3.1 Million
-108,942 Reduced 44.13%
137,914 $3.13 Million
Q1 2023

May 11, 2023

SELL
$19.47 - $28.49 $2.12 Million - $3.1 Million
-108,942 Reduced 44.13%
137,914 $3.13 Million
Q4 2022

May 14, 2024

BUY
$18.08 - $30.0 $1.16 Million - $1.93 Million
64,184 Added 35.14%
246,856 $5.81 Million
Q4 2022

Feb 13, 2023

BUY
$18.08 - $30.0 $1.16 Million - $1.93 Million
64,184 Added 35.14%
246,856 $5.81 Million
Q3 2022

May 14, 2024

BUY
$22.51 - $34.32 $1.42 Million - $2.16 Million
62,987 Added 52.63%
182,672 $4.76 Million
Q3 2022

Nov 10, 2022

BUY
$22.51 - $34.32 $1.42 Million - $2.16 Million
62,987 Added 52.63%
182,672 $4.76 Million
Q2 2022

May 14, 2024

BUY
$16.0 - $45.99 $628,736 - $1.81 Million
39,296 Added 48.88%
119,685 $2.63 Million
Q2 2022

Aug 15, 2022

BUY
$16.0 - $45.99 $903,408 - $2.6 Million
56,463 Added 89.31%
119,685 $2.63 Million
Q1 2022

May 16, 2022

SELL
$33.17 - $46.98 $271,529 - $384,578
-8,186 Reduced 11.46%
63,222 $2.84 Million
Q4 2021

Feb 14, 2022

SELL
$39.06 - $67.58 $6.1 Million - $10.5 Million
-156,106 Reduced 68.61%
71,408 $3.06 Million
Q3 2021

Nov 10, 2021

BUY
$60.13 - $77.6 $13.7 Million - $17.7 Million
227,514 New
227,514 $15.1 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.